Your session is about to expire
← Back to Search
Diagnostic Test
Lung Ultrasound for Lung Transplant
N/A
Recruiting
Led By Tathagat Narula, MD
Research Sponsored by Mayo Clinic
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up month 0 to month 12
Awards & highlights
No Placebo-Only Group
Summary
This trial is looking for a safer and cheaper way to check for lung problems in lung transplant patients without using risky procedures.
Who is the study for?
This trial is for adults over 18 who have had a lung or heart-lung transplant. They must be symptom-free, with clear chest X-rays and normal breathing test results (FEV1) that haven't dropped more than 10% from their usual. People can't join if they can't consent or have conditions like subcutaneous emphysema that make it hard to get good ultrasound images.
What is being tested?
The study is testing the use of lung ultrasounds as a non-invasive method to detect lung rejection and infection in patients who've received lung transplants. It aims to find safer ways to diagnose these serious complications without invasive procedures.
What are the potential side effects?
Since the intervention involves only lung ultrasound, which is non-invasive, there are typically no side effects associated with this procedure.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ month 0 to month 12
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~month 0 to month 12
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Establish predictive value of lung ultrasound
Awards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Receiving UltrasoundExperimental Treatment1 Intervention
Every patient will receive a lung ultrasound prior to each scheduled bronchoscopy until the study stops.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Lung ultrasound
2021
N/A
~2160
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for Bronchiectasis include antibiotics, mucoactive agents, and airway clearance techniques. Antibiotics target bacterial infections that exacerbate symptoms, reducing inflammation and preventing further lung damage.
Mucoactive agents, such as hypertonic saline, help to thin and loosen mucus, making it easier to clear from the airways. Airway clearance techniques, including chest physiotherapy and exercise, facilitate the removal of mucus, improving lung function and reducing the risk of infections.
These treatments are crucial for Bronchiectasis patients as they help manage symptoms, prevent exacerbations, and improve overall quality of life.
Self-management for bronchiectasis.Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial.
Self-management for bronchiectasis.Antibiotics for bronchiectasis exacerbations in children: rationale and study protocol for a randomised placebo-controlled trial.
Find a Location
Who is running the clinical trial?
Mayo ClinicLead Sponsor
3,326 Previous Clinical Trials
3,059,404 Total Patients Enrolled
3 Trials studying Bronchiectasis
115 Patients Enrolled for Bronchiectasis
Tathagat Narula, MDPrincipal Investigator - Mayo Clinic
Mayo Clinic Hospital Jacksonville
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You do not have any symptoms related to the medical condition being studied.You are an adult who had a heart, lung, or double organ transplant.
Research Study Groups:
This trial has the following groups:- Group 1: Receiving Ultrasound
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Share this study with friends
Copy Link
Messenger